Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

CKD and osteoporosis: Romosozumab versus Teriparatide

Comparative Effectiveness and Cardiovascular Safety of Romosozumab versus Teriparatide in Osteoporosis Patients with CKD: Target Trial Emulation Study.

Clinical journal of the American Society of Nephrology : CJASN

Citation & Authors

Clin J Am Soc Nephrol. 2026;.

Cheng-Hsien Hung; Fu-Yu Yang; Hung-En Huang; James Cheng-Chung Wei

ABSTRACT · RESEARCH SUMMARY

Research summary

This target trial emulation matched 2,045 patients per group. Romosozumab was associated with fewer vertebral fractures at 12 months (HR 0.64; 95% CI 0.42–0.98), with no significant differences in nonvertebral or hip fractures. Major cardiovascular events were also less frequent (0.82; 0.70–0.97). This observational finding requires prospective validation and does not replace existing cardiovascular safety precautions.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗